Drugs / allogeneic umbilical cord blood-derived CAR-T
allogeneic umbilical cord blood-derived CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07256353 | Dec 2025 → Dec 2030 expected | B-cell adult acute lymphocytic leukemia | The General Hospital of Western Theater Command | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allogeneic umbilical cord blood-derived CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07256353 ↗ |
| Modality | Cell therapy | “allogeneic, umbilical cord blood-derived chimeric antigen receptor T-cell (UCAR-T) therapy” NCT07256353 ↗ |
| Route | Intravenous | “intravenous injection of allogeneic umbilical cord blood-derived CAR-T” NCT07256353 ↗ |